Producer
Chirogate International Inc.
Taiwanese specialty pharmaceutical API company (HQ Taipei; listed on Taiwan Stock Exchange); specializes in chiral synthesis of complex pharmaceutical intermediates and APIs including prostaglandin analogues (latanoprost, bimatoprost, travoprost) for ophthalmic glaucoma treatment. Chirogate's prostaglandin API capability is one of a very small number of commercial-scale chiral prostaglandin synthesis operations globally. Prostaglandin analogues require control of multiple stereocenters — including the stereochemistry of the cyclopentyl ring system and aliphatic chain — in molecules that cost $1M+ per kilogram due to the extreme chemical synthesis challenge. Chirogate's expertise in asymmetric synthesis for prostaglandins demonstrates that small Taiwanese specialty chemistry companies can hold critical supply chain positions in global pharmaceutical markets — ophthalmic surgeons worldwide depend on APIs from a company most of their patients have never heard of.
1
Inputs supplied
1
Goods downstream
0
Facilities
0
Stories
What they make
1 input Chirogate International Inc. supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Chirogate International Inc. makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Prostaglandin Analogue APIs (Ophthalmic)
70%Specialty Chiral APIs & Intermediates
25%Research & Contract Synthesis
5%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Chokepoint2024
Chirogate International holds a structural chokepoint in global glaucoma treatment: prostaglandin analogue APIs (latanoprost, bimatoprost, travoprost) require commercial-scale chiral synthesis capacity that fewer than five companies worldwide possess. Glaucoma affects approximately 80 million people globally and is the second leading cause of irreversible blindness. The prostaglandin analogue eye drops that prevent disease progression require APIs synthesized from the same Taiwan-based company that most ophthalmologists, patients, and pharmaceutical supply chain managers have never heard of. Chirogate' s small size (relative to global pharma) and concentrated Taiwan production base means that a plant incident, regulatory action, or political disruption in Taiwan would directly affect the global supply of the primary pharmacological treatment for a disease threatening the vision of 80 million patients. The API behind latanoprost (Xalatan, the world's best-selling prostaglandin glaucoma drug before going generic) flows through a tiny Taipei company.
Chirogate International Inc. ↗Origin2023
Chirogate International was founded in Taipei specifically to build chiral synthesis capabilities for complex pharmaceutical APIs that require precise control of multiple stereocenters. The company positioned itself in the late 1990s-2000s to serve the ophthalmic prostaglandin market — a technically demanding segment where the API synthesis requires enzymatic resolution or asymmetric catalysis to produce a single enantiomer from a racemic mixture. Prostaglandin F2-alpha analogues (latanoprost, bimatoprost, travoprost) are among the most synthetically complex generic APIs commercially produced — the cyclopentane ring with two or three stereocenters and the chiral aliphatic chain make each stereospecific step critical. Chirogate' s willingness to invest in this chemistry, while most API companies chose simpler generics, resulted in it holding a structural position in global glaucoma API supply with very few competitors at commercial scale.
Chirogate International Inc. ↗